Kristian Stengaard-Pedersen

Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Line Dam Heftdal
  • ,
  • Kristian Stengaard-Pedersen
  • Lykke Midtbøll Ørnbjerg, c Center for Rheumatology and Spine Diseases , Copenhagen Center for Arthritis Research, Rigshospitalet , Glostrup , Denmark.
  • ,
  • Merete Lund Hetland, d Department of Clinical Medicine , Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark.
  • ,
  • Kim Hørslev-Petersen, f Institute of Health Research , University of Southern Denmark , Odense , Denmark.
  • ,
  • Peter Junker, g Department of Rheumatology , Odense University Hospital , Odense , Denmark.
  • ,
  • Mikkel Østergaard, d Department of Clinical Medicine , Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark.
  • ,
  • Malene Hvid
  • Bent Deleuran
  • Holger Jon Møller
  • Stinne Ravn Greisen
Rheumatoid arthritis (RA) is characterized by chronic joint inflammation and infiltration by activated macrophages. TNFα is a central mediator in this process. The mannose receptor, CD206, is a scavenger receptor expressed by M2A-macrophages and dendritic cells. It is involved in collagen internalization and degradation. The soluble form has been suggested as a biomarker of M2A-macrophage activation. The aim of this study was to investigate sCD206 plasma levels in early RA patients initiating anti-TNFα treatment. Plasma levels of sCD206 were measured by ELISA in samples from 155 early RA patients with an average symptom duration of 3 months. Patients were randomized to 12 months’ methotrexate and placebo (PLA) or methotrexate and adalimumab (ADA) treatment, followed by open-label treatment with disease-modifying anti-rheumatic drugs (DMARD) and if needed, ADA. Disease activity was assessed at baseline and after 3, 6, 12 and 24 months. Baseline plasma level of sCD206 in treatment naïve RA patients was 0.33 mg/L (CI: 0.33–0.38 mg/L) corresponding to the upper part of the reference interval for healthy controls (0.10–0.43 mg/L). In the PLA group, sCD206 levels decreased after 3 months, but did not differ from baseline after 6 months. In the ADA group, however, levels remained lower than baseline throughout the treatment period. In conclusion, initially, plasma sCD206 in early RA patients decreased in accordance with disease activity and initiation of DMARD treatment. Treatment with anti-TNFα preserved this decrease throughout the study period.
Original languageEnglish
JournalScandinavian Journal of Clinical & Laboratory Investigation
Pages (from-to)385-389
Number of pages5
Publication statusPublished - Sep 2017

    Research areas

  • Cluster of differentiation, Macrophages, Mannose-Binding Lectin, Rheumatoid arthritis, Tumor necrosis factor-alpha

See relations at Aarhus University Citationformats

ID: 120500880